AC Immune Advances Anti-pTau Active Immunotherapy For Alzheimer's Disease Into Phase 2b Trial

RTTNews | 320 दिनों पहले

(RTTNews) - Swiss biopharmaceutical company AC Immune SA (ACIU) announced Friday that its development partner has programmed the launch of a Phase 2b clinical study to evaluate ACI-35.030 (JNJ-64042056) in patients with preclinical Alzheimer's disease (AD), those individuals not yet showing symptoms.

ACI-35.030 is an investigational targeted active immunotherapy, selective for pathological phosphorylated Tau (pTau). Studies have shown that pTau correlates with AD progression and the trial aims to show that ACI-35.030 can prevent or slow down the progression of tau pathology and onset of clinical symptoms.

Under the terms of the licensing agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson (JNJ) company, AC Immune will now receive a milestone payment of CHF 15 million and will receive another milestone payment of CHF 25 million related to achieving a non-disclosed enrollment target.

The partnership with Janssen aims to develop and commercialize therapeutic anti-Tau active immunotherapies for the treatment of AD and potentially other Tauopathies.

The Phase 2b ReTain trial is a potentially registration-enabling trial and is a randomized, multicenter, double-blind, placebo-controlled clinical study in participants with preclinical AD to assess the clinical effect of active immunization with ACI-35.030.

The Phase 2b study (ReTain) will evaluate the effect of ACI-35.030 on cognition and Tau pathology in approximately 500 participants with preclinical Alzheimer's disease (AD).

टैग: JNJ ACIU

Johnson & Johnson Q2 Adj. EPS Beats View, Cuts FY24 Earnings Forecast

Johnson & Johnson reported Wednesday weak profit in its second quarter on charges, while adjusted earnings beat market estimates on sales growth. The drug major further trimmed its fiscal 2024 adjusted earnings outlook, but lifted operational sales view to mainly reflect the acquisition of Shockwave Medical. In pre-market activity on the NYSE, Johnson & Johnson shares were losing around 0.5...

RTTNews | 105 दिनों पहले

Johnson & Johnson To Acquire Rights To Numab Therapeutics' Clinical-Stage Bispecific Antibody NM26

Johnson & Johnson (JNJ) announced Tuesday it has entered into a definitive agreement with biotechnology company Numab Therapeutics to acquire its wholly-owned subsidiary from Numab's shareholders in an all-cash transaction of approximately $1.25 billion.

RTTNews | 155 दिनों पहले

J&J Seeks EMA Approval For DARZALEX Quadruplet Therapy For Multiple Myeloma

Janssen-Cilag International NV, a Johnson & Johnson company (JNJ), announced Wednesday the submission of a Type II variation application to the European Medicines Agency (EMA).

RTTNews | 238 दिनों पहले

Integra LifeSciences To Acquire Acclarent For $275 Mln Cash

Medical technology firm Integra LifeSciences Holdings Corp. (IART) announced Wednesday that it has entered into a definitive agreement to acquire Acclarent, Inc. from Ethicon, Inc., a Johnson & Johnson MedTech company, for $275 million in cash at closing. This is subject to customary purchase price adjustments, and an additional $5 million upon the achievement of certain regulatory milestones.

RTTNews | 322 दिनों पहले

Johnson & Johnson Guides FY24 Adj. EPS Below Estimates

Ahead of the meeting with the investment community at the New York Stock Exchange later on Tuesday, Johnson & Johnson (JNJ) initiated financial guidance for the full-year 2024 and for the long term.

RTTNews | 330 दिनों पहले

Johnson & Johnson Trims FY23 Earnings, Net Sales Outlook

Healthcare company Johnson & Johnson (JNJ) on Wednesday updated its first-half financials and fiscal 2023 guidance which reflect its continuing operations as a company focused on transformational innovation in Pharmaceutical and MedTech, following the separation of Kenvue Inc., formerly Johnson & Johnson's Consumer Health business.

RTTNews | 427 दिनों पहले

Court Rejects J&J Bankruptcy Petition To End Talc Cancer Lawsuits

A U.S. appeals court has rejected Johnson & Johnson's bankruptcy move, saying that it can't escape from nearly 40,000 lawsuits filed by women who claimed to have developed ovarian cancer after using its asbestos contained talcum powder products. J&J, which already withdrew its talc-based baby powder, is now required to defend itself against these thousands of ovarian cancer claims.

RTTNews | 638 दिनों पहले

Johnson & Johnson Q4 Profit Down 26%, But Adj. EPS Tops Estimates

Healthcare company Johnson & Johnson on Tuesday reported that profit for fourth quarter declined 25.9 percent from last year, reflecting a sales decline and higher provisions for income taxes. Adjusted earnings per share topped analysts' expectations, while quarterly revenues missed it by a whisker. The company also initiated operational earnings forecast for the full-year 2023.

RTTNews | 645 दिनों पहले

EURUSD	1.08363	GBPUSD	1.30016	AUDUSD	0.65757
USDJPY	153.162	USDCAD	1.3912	USDCHF	0.8667